March 1 (SeeNews) - Romanian pharmaceuticals company Zentiva [BSE:SCD], part of Zentiva Group Romania, said that its net profit rose by an annual 92.2% to 191.1 million lei ($41.5 million/38.4 million euro) in 2023.
The improved profitability was mainly due to the increase in sales of goods and services, with revenue climbing 24.5% on the year to 945.7 million lei, Zentiva said in an interim financial report filed with the Bucharest Stock Exchange on Thursday.
Operating profit rose to 182.8 million lei during the twelve months through December, from 86.3 million lei during the year before.
Zentiva Group Romania brings together Zentiva SA, Labormed-Pharma, Labormed Pharma Trading (formerly Alvogen Romania), Be Well Pharma and Solacium Pharma.
Zentiva's shares traded 3.45% higher at 3 lei as of 1519 CET on Friday on the Bucharest bourse.
(1 euro=4.96990 lei)